Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wuxi AppTec CoWUXIF -4.76%75 EV-to-EBITDA is 13.32 as of Jul. 28, 2026, which is 57% below its 10-year median of 31.26. GuruFocus rates WUXIF with a GF Score™ of 75/100 and a GF Value™ of $12.43 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 117 Medical Diagnostics & Research companies, Wuxi AppTec Co ranks better than 57.26% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Wuxi AppTec Co's enterprise value is $48,144 Mil.
Wuxi AppTec Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $3,615 Mil. Therefore, Wuxi AppTec Co's EV-to-EBITDA for today is 13.32.
The historical rank and industry rank for Wuxi AppTec Co's EV-to-EBITDA or its related term are showing as below:
WUXIF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.1 Med: 31.26 Max: 122.44
Current: 13.32
During the past 12 years, the highest EV-to-EBITDA of Wuxi AppTec Co was 122.44. The lowest was 9.10. And the median was 31.26.
WUXIF's EV-to-EBITDA is ranked better than 57.26% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 14.28
vs WUXIF: 13.32
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Wuxi AppTec Co (OTCPK:WUXIF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Wuxi AppTec Co's PE Ratio (TTM) for today is calculated as:
Wuxi AppTec Co's share price for today is $21.62.
Wuxi AppTec Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.979.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Wuxi AppTec Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Wuxi AppTec Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuxi AppTec Co EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Wuxi AppTec Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Wuxi AppTec Co's EV-to-EBITDA falls into.
Wuxi AppTec Co's current Enterprise Value is $48,144 Mil.
Wuxi AppTec Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3,615 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuxi AppTec Co (WUXIF) has a EV-to-EBITDA of 13.32 as of Jul. 28, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Wuxi AppTec Co. This is 57% below median its historical median of 31.26. Over the past decade, Wuxi AppTec Co's EV-to-EBITDA has ranged from 9.10 to 122.44. According to the industry distribution chart, Wuxi AppTec Co ranks #50 out of 117 companies in the Medical Diagnostics & Research industry, placing it in the top 42.7%.
Is Wuxi AppTec Co's EV-to-EBITDA too high?
Wuxi AppTec Co's current EV-to-EBITDA of 13.32 is 57% below median its 10-year median of 31.26. Over the past 10 years, this metric has ranged from a low of 9.10 to a high of 122.44. The Medical Diagnostics & Research industry median EV-to-EBITDA is 14.28. Wuxi AppTec Co's value of 13.32 is 6.7% below this industry median. Based on the distribution chart, Wuxi AppTec Co ranks #50 out of 117 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Wuxi AppTec Co has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wuxi AppTec Co's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Wuxi AppTec Co ranks #50 out of 117 companies for EV-to-EBITDA. This puts Wuxi AppTec Co in the upper half of its industry. The industry median EV-to-EBITDA is 14.28. Wuxi AppTec Co's value of 13.32 is 6.7% below this benchmark. Historically, Wuxi AppTec Co's own EV-to-EBITDA has ranged from 9.10 to 122.44 over the past decade. While the company's 10-year median is 31.26 vs. the industry median of 14.28, Wuxi AppTec Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 14.28, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wuxi AppTec Co's current EV-to-EBITDA of 13.32 is 6.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Wuxi AppTec Co. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 14.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wuxi AppTec Co's current EV-to-EBITDA is 13.32, which is 57% below median its own 10-year median of 31.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuxi AppTec Co stock overvalued right now?
Based on GuruFocus' analysis, Wuxi AppTec Co (WUXIF) is currently considered Significantly Overvalued. The stock's GF Value™ is $12.43, compared to a current price of $21.62 — trading 73.9% above its estimated fair value. The current EV-to-EBITDA is 13.32, which is 57% below median its 10-year median of 31.26 and 6.7% below the Medical Diagnostics & Research industry median of 14.28. Wuxi AppTec Co's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Wuxi AppTec Co (WUXIF), the current EV-to-EBITDA is 13.32 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wuxi AppTec Co (WUXIF) Overvalued in 2026?
Based on GuruFocus' analysis, Wuxi AppTec Co stock appears to be overvalued.
The current stock price of $21.62 is trading 73.9% above its estimated GF Value™ of $12.43.
GuruFocus considers Wuxi AppTec Co to be Significantly Overvalued.
Key valuation signals for WUXIF:
EV-to-EBITDA: 13.32 (57% below median its 10-year median of 31.26)
GF Value™: $12.43 vs. price of $21.62 (73.9% above fair value)
Industry Position: 6.7% below the Medical Diagnostics & Research median (#50 of 117)
No single metric tells the full story. See the WUXIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, and manufacturing spectrum for small molecule drugs, development of computer software and databases as well as consulting services for combinatorial chemistry and pharmaceuticals. The services offered by the company include drug research and development testing, clinical research services, an end-to-end CRDMO platform for peptide, oligonucleotide, and small molecules, and integrated biology services and solutions for drug discovery. The company's reportable segments are WuXi Chemistry, which derives maximum revenue, WuXi Testing, WuXi Biology, and Others. Geographically, it derives key revenue from the United States of America, followed by PRC, Europe, and other regions.
75GF Score
Get the complete analysis for WUXIF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WUXIF has been successfully added to your 
